STOCK TITAN
  1. Home
  2. News
  3. NBY

Novabay Pharmaceuticals Inc - NBY STOCK NEWS

Welcome to our dedicated news page for Novabay Pharmaceuticals (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novabay Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novabay Pharmaceuticals's position in the market.

News
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) announces a new and enhanced direct-to-consumer marketing program to boost Avenova sales. The program includes SMS and targeted email marketing to engage customers and drive online sales. The company aims to enhance customer loyalty, reach new prospective customers, and capitalize on the success of previous marketing efforts through social media and email channels. CEO Justin Hall highlights the positive impact of the SMS program on customer engagement and reveals significant sales growth from social media and email campaigns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) received a notice from NYSE American regarding non-compliance with listing standards due to stockholders equity. The company must submit a plan by May 18, 2024, to regain compliance by October 18, 2025. The notice has no immediate effect on stock trading or business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Rhea-AI Summary
NovaBay Pharmaceuticals reported a 13% increase in eyecare and wound care revenue for the first quarter of 2024, reaching $2.6 million. The growth was driven by efficient e-marketing programs for their lead product, Avenova Antimicrobial Lid & Lash Solution, resulting in lower sales and marketing expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) reports a 10% increase in Q4 net sales from the eyecare and wound care segment, driven by higher Avenova® sales through physician dispensed and OTC channels. Sales and marketing expenses decreased by 27%, with a divestiture of the skincare segment expected to boost cash position. The company continues its eyecare growth strategy with a co-marketing partnership and achieved a 64% increase in online subscription-based unit sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
earnings
-
News
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) will release financial results for the three and 12 months ending December 31, 2023, followed by an investor conference call on March 26, 2024. Pre-registration for the call is available, with dial-in options for immediate access. The webcast will be accessible on the Company website, with a replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
none
-
News
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) announces the sale of its DERMAdoctor skincare business for $1.0 million in cash to reduce operating expenses and strengthen cash reserves. The sale aims to streamline the business, allowing for a focus on core products like Avenova. The company also reveals a partnership with Eyenovia for marketing FDA-approved products, anticipating net sales of $14.7 million for 2023 with an operating loss of $7.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
earnings
News
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) reports a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. Avenova Spray averaged a 4.5-star overall rating across all online channels, with over 13,000 customer reviews. The CEO, Justin Hall, attributes the success to the superior quality and effectiveness of the product. The company also expanded its Avenova portfolio of products, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops, Avenova Warm Eye Compress, and the i-Chek by Avenova. Additionally, the Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
News
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products in the European Union. Sonoma will combine its existing eye product Ocudox with Avenova branding and market it through its established European distribution network. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
-
News
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) and Sonoma Pharmaceuticals, Inc. (SNOA) have announced an agreement for the sale and marketing of Avenova-branded products by Sonoma in the European Union. The products will combine Sonoma's existing eye product Ocudox with Avenova branding and will be marketed through Sonoma's established European distribution network. Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay's Avenova products and will pay NovaBay a royalty fee based on net product sales. This agreement allows NovaBay to capitalize on sales of hypochlorous acid eye care products in the European Union, potentially doubling its sales of Avenova. NovaBay will continue to be the exclusive seller of Avenova branded products in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
News
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
Rhea-AI Summary
NovaBay Pharmaceuticals, Inc. (NBY) partners with Woo University to educate eyecare professionals on amniotic membranes. The company recently launched Avenova® Allograft, a prescription amniotic membrane product. The partnership aims to support optometric continuing education through a free webinar featuring experts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
partnership
Stock NBY logo
Novabay Pharmaceuticals Inc

NYSE:NBY

NBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NBY Stock Data

2.72M
29.93M
0.04%
3.95%
2.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Emeryville

About NBY

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across